Pharmaceuticals - ASEAN

  • ASEAN
  • The Pharmaceuticals market in ASEAN is predicted to achieve a revenue of US$14.28bn by 2024.
  • among the various markets, Oncology Drugs is expected to dominate the market with a projected market volume of US$2.17bn in 2024.
  • The industry is anticipated to witness a steady annual growth rate (CAGR 2024-2029) of 4.03%, resulting in a market volume of US$17.40bn by 2029.
  • In terms of global comparison, United States is forecasted to generate the highest revenue of US$630.30bn in 2024.
  • In the ASEAN region, Singapore's pharmaceutical market is thriving due to its strong research and development capabilities.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in ASEAN has been experiencing significant growth in recent years, with several underlying macroeconomic factors driving this trend.

Customer preferences:
Customers in the ASEAN region have become increasingly health-conscious, leading to a growing demand for pharmaceutical products. Additionally, the aging population in many ASEAN countries has resulted in a higher prevalence of chronic diseases, further fueling the demand for pharmaceuticals.

Trends in the market:
One of the key trends in the ASEAN pharmaceutical market is the increasing focus on generic drugs. With rising healthcare costs, many governments in the region are encouraging the use of generic drugs as a cost-saving measure. This has led to increased competition among pharmaceutical companies, with many focusing on developing high-quality, low-cost generic drugs.Another trend is the growing importance of digital technologies in the pharmaceutical industry. Many companies are investing in digital tools to improve drug development processes, enhance patient outcomes, and streamline supply chain management.

Local special circumstances:
Each ASEAN country has its own unique market dynamics, which can impact the pharmaceutical industry in different ways. For example, in Indonesia, the government has implemented policies to promote the local production of pharmaceuticals, which has led to increased investment in the sector. In Thailand, the government has implemented a universal healthcare system, which has led to increased demand for pharmaceutical products.

Underlying macroeconomic factors:
Several macroeconomic factors are driving the growth of the pharmaceutical industry in ASEAN. One of the most significant is the region's rapid economic growth, which has led to rising incomes and increased healthcare spending. Additionally, the ASEAN region is home to a large and growing population, which further drives demand for pharmaceutical products.Another key factor is the increasing prevalence of chronic diseases in the region, such as diabetes, cardiovascular disease, and cancer. This has led to a growing need for pharmaceutical products to treat these conditions.Overall, the pharmaceutical industry in ASEAN is poised for continued growth in the coming years, driven by a combination of macroeconomic factors, changing customer preferences, and technological advancements.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)